Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Payables (2016 - 2025)

Historic Payables for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $6.1 million.

  • Sunshine Biopharma's Payables rose 4763.27% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year increase of 4763.27%. This contributed to the annual value of $5.5 million for FY2024, which is 11439.4% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Payables is $6.1 million, which was up 4763.27% from $4.8 million recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Payables high stood at $6.1 million for Q3 2025, and its period low was $95234.0 during Q1 2022.
  • For the 5-year period, Sunshine Biopharma's Payables averaged around $2.7 million, with its median value being $2.6 million (2023).
  • Its Payables has fluctuated over the past 5 years, first crashed by 8577.73% in 2022, then skyrocketed by 277308.52% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Payables (Quarter) stood at $1.9 million in 2021, then soared by 44.26% to $2.8 million in 2022, then dropped by 7.75% to $2.6 million in 2023, then skyrocketed by 114.39% to $5.5 million in 2024, then increased by 10.72% to $6.1 million in 2025.
  • Its Payables was $6.1 million in Q3 2025, compared to $4.8 million in Q2 2025 and $5.0 million in Q1 2025.